8,175 Moderna, Inc. $MRNA Shares Sold by Montaka Global Pty Ltd

Montaka Global Pty Ltd cut its position in Moderna, Inc. (NASDAQ:MRNA) by 41.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,775 shares of the company’s stock after selling 8,175 shares during the quarter. Moderna comprises about 0.9% of Montaka Global Pty Ltd’s holdings, making the stock its 24th largest position. Montaka Global Pty Ltd’s holdings in Moderna were worth $2,268,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Lido Advisors LLC raised its stake in Moderna by 0.5% in the 3rd quarter. Lido Advisors LLC now owns 16,605 shares of the company’s stock valued at $3,198,000 after acquiring an additional 83 shares during the period. Keybank National Association OH lifted its holdings in Moderna by 5.6% during the third quarter. Keybank National Association OH now owns 9,581 shares of the company’s stock valued at $1,845,000 after purchasing an additional 512 shares during the last quarter. 71 West Capital Partners purchased a new stake in Moderna during the third quarter valued at about $494,000. Gryphon Financial Partners LLC purchased a new stake in Moderna during the third quarter valued at about $470,000. Finally, AlphaCore Capital LLC bought a new position in Moderna during the third quarter worth about $499,000. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Wall Street Analysts Forecast Growth

MRNA has been the subject of several recent research reports. Brookline Capital Markets reiterated a “buy” rating on shares of Moderna in a research note on Wednesday, August 19th. Royal Bank Of Canada restated a “sector perform” rating and set a $130.00 price target on shares of Moderna in a research note on Wednesday, August 19th. Berenberg Bank upped their price target on shares of Moderna from $45.00 to $100.00 and gave the company a “hold” rating in a research note on Friday, September 11th. TD Cowen reaffirmed a “buy” rating on shares of Moderna in a report on Wednesday, October 21st. Finally, Wolfe Research upgraded shares of Moderna from an “underperform” rating to a “peer perform” rating in a research note on Tuesday, August 25th. Six analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $113.75.

Insider Buying and Selling

In other Moderna news, insider Shannon Klinger sold 3,471 shares of the stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $139.95, for a total value of $485,766.45. Following the sale, the insider directly owned 74,129 shares in the company, valued at $10,374,353.55. This represents a 4.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Jamey Mock sold 34,836 shares of the stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $134.49, for a total transaction of $4,685,093.64. Following the completion of the sale, the chief financial officer owned 59,375 shares in the company, valued at $7,985,343.75. This represents a 36.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 197,251 shares of company stock valued at $33,875,904. Company insiders own 10.80% of the company’s stock.

Key Stories Impacting Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna reported third-quarter revenue of about $1.3 billion, up 29% year over year and ahead of expectations, and raised its 2026 revenue-growth outlook to 15%–25%. Lower costs and respiratory-vaccine gains also supported the improved outlook. Why is Moderna stock soaring today?
• Positive Sentiment: Investors also have a potential longer-term catalyst in personalized cancer vaccine intismeran. Phase 3 results reportedly showed a 42% reduction in melanoma recurrence or death, and Moderna is targeting an FDA filing by year-end 2026, which could lead to a decision in 2027. Can Moderna’s first cancer therapy win FDA approval in 2027?
• Neutral Sentiment: Moderna is scheduled to present at the Jefferies Global Health Care Conference on November 18. The event could provide updates, but the announcement itself does not change the company’s outlook. Moderna to present at upcoming conference
• Negative Sentiment: Despite the earnings beat, nearly all of Moderna’s revenue still comes from COVID-related products, leaving investors focused on the challenge of building durable sales beyond the pandemic market. That concern may weigh more heavily after the stock’s sharp recent run. Moderna’s Q3 numbers may not be enough to make the stock a buy
• Negative Sentiment: Valuation is another headwind: Goldman Sachs raised its price target but kept a neutral rating, while a separate analysis put fair value well below the prevailing share price. Brookline also made modest reductions to its long-term earnings estimates, despite maintaining a Buy rating.

Moderna Trading Down 6.8%

Shares of MRNA opened at $250.83 on Wednesday. Moderna, Inc. has a twelve month low of $22.28 and a twelve month high of $280.80. The stock has a market cap of $101.49 billion, a PE ratio of -35.33 and a beta of 1.16. The company has a quick ratio of 3.47, a current ratio of 3.62 and a debt-to-equity ratio of 0.52. The business’s 50-day moving average price is $196.68 and its 200-day moving average price is $93.60.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Friday, November 6th. The company reported $0.38 EPS for the quarter, beating analysts’ consensus estimates of ($1.10) by $1.48. The company had revenue of $1.31 billion during the quarter, compared to analyst estimates of $890.25 million. Moderna had a negative net margin of 110.46% and a negative return on equity of 25.79%. Moderna’s revenue was up 29.2% compared to the same quarter last year. During the same period last year, the business earned ($0.51) earnings per share. On average, equities analysts forecast that Moderna, Inc. will post -5.69 EPS for the current fiscal year.

Moderna Company Profile

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.